LQT-1213

DRUG2 trials

Sponsors

Thryv Therapeutics, Inc.

Conditions

Long QT Syndrome

Phase 1

Phase 1 Study of LQT-1213 in Healthy Adults

CompletedNCT05759962

Thryv Therapeutics, Inc.Long QT Syndrome

Start: 2022-09-14End: 2023-03-05Updated: 2023-09-26

Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2).

TerminatedNCT05906732

Thryv Therapeutics, Inc.Long QT Syndrome

Start: 2023-03-12End: 2024-05-31Updated: 2025-07-24